|Bid||28.65 x N/A|
|Ask||28.67 x N/A|
|Day's Range||28.53 - 29.49|
|52 Week Range||26.52 - 47.60|
|Beta (5Y Monthly)||1.21|
|PE Ratio (TTM)||8.89|
|Earnings Date||Aug 02, 2022|
|Forward Dividend & Yield||0.92 (3.16%)|
|Ex-Dividend Date||May 16, 2022|
|1y Target Est||44.69|
Subscribe to Yahoo Finance Plus to view Fair Value for FRE.DE
German healthcare group Fresenius's first-quarter profit exceeded market expectations on Wednesday, driven by growth in its generic infusion drugs unit in emerging markets. However, the group warned cost inflation and supply chain disruptions were likely to increase this year, fuelled by Russia's invasion of Ukraine. Fresenius's businesses include the Helios hospital chain, drugmaker Kabi, medical services firm Vamed and dialysis specialist Fresenius Medical Care (FMC).
The Russian invasion of Ukraine has brought the terms risk-on and risk-off into play as investors try to figure out the best stocks to buy in such a volatile market. A war of such magnitude is a headwind for stocks. As such, they’re currently considered risk-on assets. In times like these, investors look for risk-off assets such as gold, U.S. dollars, dollar-denominated bonds, and even Bitcoin (BTC-USD). The reality is that, try as we may, there is no such thing as a risk-off or risk-on asset. T
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Fresenius SE & Co. KGaAGlobal Credit Research - 08 Dec 2021Frankfurt am Main, December 08, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius SE & Co. KGaA and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 6 December 2021 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. Since 1 January 2019, Moody's practice has been to issue a press release following each periodic review to announce its completion.This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.